Posters
« Back
CiPA Phase 2 Study: validation of an automated microelectrode array (MEA) assay of hiPSC-derived cardiomyocyte electrophysiology for cardiac safety evaluation
EP25576
Poster Title: CiPA Phase 2 Study: validation of an automated microelectrode array (MEA) assay of hiPSC-derived cardiomyocyte electrophysiology for cardiac safety evaluation
Submitted on 17 Feb 2017
Author(s): DC Millard, AM Nicolini, SA Chvatal, HB Hayes, M Clements, JD Ross
Affiliations: Axion BioSystems
This poster was presented at Stem Cells in Drug Discovery 2017
Poster Views: 1,184
View poster »


Poster Information
Abstract: The Comprehensive in vitro Proarrhythmia Assay (CiPA), led by the US Food and Drug Administration, aims to reduce unwarranted drug attrition by improving preclinical cardiac safety evaluation. A key component of the proposed assay utilizes human stem cell derived cardiomyocytes (hSC-CMs) and microelectrode array (MEA) technology to evaluate the proarrhythmic risk of candidate compounds [1]. An initial pilot study with 8 blinded compounds demonstrated reproducible results across 10 studies. The CiPA Phase 2 study with 28 blinded compounds was established to evaluate the ability of the CM-MEA assay to assess proarrhythmic risk. The increased scale of the CiPA Phase 2 study was used as a case study in the development and validation of an automated CM-MEA assay for cardiac safety evaluation.
The iCell Cardiomyocyte2 and Maestro APEX automated MEA workstation were used to evaluate 28 compounds of high, intermediate, and low proarrhythmic risk in a blinded study. The amplitude and field potential duration (FPD) were extracted from the raw field potential signal for each replicate and compound, providing information on the depolarization and repolarization of the cardiomyocyte monolayers, respectively. Additional beating characteristics, such as the beating rate, variability in beat rate, and occurrence of EADs were also included in the analysis. Corrected field potential duration (FPDc) was computed using the Fridericia correction.
These results support the use of hSC-CM and MEA technology for preclinical assessment of proarrhythmic risk within the proposed CiPA paradigm, and, more generally, demonstrate that automation of the CM-MEA assay can achieve high reliability and throughput for cardiac risk assessment in vitro.
Summary: These results support the use of human stem cell derived cardiomyocytes (hSC-CMs) and microelectrode array (MEA) technology for preclinical assessment of proarrhythmic risk within the proposed CiPA paradigm, and, more generally, demonstrate that automation of the CM-MEA assay can achieve high reliability and throughput for cardiac risk assessment in vitro.References: [1] Millard, D. C., Clements, M., and Ross, J. D. (2016). The CiPA Microelectrode Array Assay with hSC-Derived Cardiomyocytes: Current Protocol, Future Potential. Stem Cell-Derived Models in Toxicology, pp.83-107
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


Potential therapeutic effects of induced pluripotent stem cells on induced salivary gland cancer in experimental rats
Yasmine Alaa El-Din1, Dina Sabry2, Amal Hassan Abdelrahman3, and Safa Fathy3

Improved Expansion of Neural Stem Cells with Gibcoâ„¢ Heat Stable Recombinant Human Basic Fibroblast Growth Factor
Brittany Balhouse, Diana Navarro, Richard Josephson, and Matthew Dallas

Novel Engineered Basic Fibroblast Growth Factor Improves Stability and Enables Improved Cell Culture Outcomes
Brittany Balhouse, Diana Navarro, Richard Josephson, and Matthew Dallas

Strategies for High-Titer Protein Expression Using the ExpiCHO and Expi293 Transient Expression Systems
Chao Yan Liu, Jian Liu, Wanhua Yan, Kyle Williston, Katy Irvin, Henry Chou, Jonathan Zmuda

A Chemically-Defined Baculovirus-Based Expression System for Enhanced Protein Production in Sf9 Cells
Maya Yovcheva, Sara Barnes, Kenneth Thompson, Melissa Cross, Katy Irvin, Mintu Desai, Natasha Lucki, Henry Chiou, Jonathan Zmuda